Redhill Biopharma Net Worth
Redhill Biopharma Net Worth Breakdown | RDHL |
Redhill Biopharma Net Worth Analysis
Redhill Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Redhill Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Redhill Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Redhill Biopharma's net worth analysis. One common approach is to calculate Redhill Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Redhill Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Redhill Biopharma's net worth. This approach calculates the present value of Redhill Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Redhill Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Redhill Biopharma's net worth. This involves comparing Redhill Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Redhill Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Redhill Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Redhill Biopharma's net worth research are outlined below:
| Redhill Biopharma generated a negative expected return over the last 90 days | |
| Redhill Biopharma has some characteristics of a very speculative penny stock | |
| Redhill Biopharma has high historical volatility and very poor performance | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Redhill Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Redhill Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Redhill Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Redhill to invest in growth at high rates of return. When we think about Redhill Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Redhill Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: 3 Stocks with Growth Prospects in the Triple Digits - AOL |
Redhill Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Redhill Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Redhill Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Redhill Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Redhill Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Redhill Biopharma backward and forwards among themselves. Redhill Biopharma's institutional investor refers to the entity that pools money to purchase Redhill Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2023-12-31 | 104 | Ubs Group Ag | 2023-12-31 | 104 | Bank Of America Corp | 2023-12-31 | 82.0 | Atlantic Edge Private Wealth Management Llc | 2023-12-31 | 25.0 | Wells Fargo & Co | 2023-12-31 | 23.0 | Jpmorgan Chase & Co | 2023-12-31 | 8.0 | Ifp Advisors, Llc | 2023-12-31 | 7.0 | Cowen And Company, Llc | 2023-09-30 | 0.0 | Virtu Financial Llc | 2023-12-31 | 0.0 | Gagnon Securities Llc | 2023-12-31 | 89.6 K | Jane Street Group, Llc | 2023-12-31 | 86.8 K |
Follow Redhill Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Redhill Biopharma's market, we take the total number of its shares issued and multiply it by Redhill Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Redhill Biopharma's profitablity
Redhill Biopharma's profitability indicators refer to fundamental financial ratios that showcase Redhill Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Redhill Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Redhill Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Redhill Biopharma's profitability requires more research than a typical breakdown of Redhill Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 1.37 | 1.44 | |
| Return On Capital Employed | (8.24) | (7.83) | |
| Return On Assets | 1.04 | 1.09 | |
| Return On Equity | 11.56 | 12.14 |
When accessing Redhill Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Redhill Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Redhill Biopharma's profitability and make more informed investment decisions.
The data published in Redhill Biopharma's official financial statements usually reflect Redhill Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Redhill Biopharma. For example, before you start analyzing numbers published by Redhill accountants, it's critical to develop an understanding of what Redhill Biopharma's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Redhill Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Redhill Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Redhill Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Redhill Biopharma. Please utilize our Beneish M Score to check the likelihood of Redhill Biopharma's management manipulating its earnings.
Evaluate Redhill Biopharma's management efficiency
Redhill Biopharma has return on total asset (ROA) of (0.1571) % which means that it has lost $0.1571 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.8429) %, meaning that it created substantial loss on money invested by shareholders. Redhill Biopharma's management efficiency ratios could be used to measure how well Redhill Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Redhill Biopharma's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 1.09 this year, although the value of Return On Capital Employed is projected to rise to (7.83). At this time, Redhill Biopharma's Other Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 1.44 this year, although the value of Other Current Assets will most likely fall to about 757.2 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.32 | 0.30 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (0.54) | (0.51) | |
| Enterprise Value Over EBITDA | (0.15) | (0.15) | |
| Price Book Value Ratio | 4.57 | 4.17 | |
| Enterprise Value Multiple | (0.15) | (0.15) | |
| Price Fair Value | 4.57 | 4.17 | |
| Enterprise Value | 4.3 M | 4.1 M |
The analysis of Redhill Biopharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Redhill Biopharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Redhill Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 1.4028 | Revenue 6.5 M | Quarterly Revenue Growth (0.96) | Revenue Per Share 1.008 | Return On Equity (8.84) |
Redhill Biopharma Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Redhill Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Redhill Biopharma Corporate Management
Elected by the shareholders, the Redhill Biopharma's board of directors comprises two types of representatives: Redhill Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Redhill. The board's role is to monitor Redhill Biopharma's management team and ensure that shareholders' interests are well served. Redhill Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Redhill Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Reza Fathi | Senior Development | Profile | |
| Kristin Comer | G VP | Profile | |
| Valerie Graceffa | VP Sales | Profile | |
| Razi Ingber | Chief Officer | Profile | |
| Rob Jackson | VP Marketing | Profile |
How to buy Redhill Stock?
The net worth of Redhill Biopharma is the difference between its total assets and liabilities. Redhill Biopharma's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Redhill Biopharma's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Redhill Biopharma's net worth can be used as a measure of its financial health and stability which can help investors to decide if Redhill Biopharma is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Redhill Biopharma stock.Already Invested in Redhill Biopharma?
The danger of trading Redhill Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Redhill Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Redhill Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Redhill Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.